1
|
Zhang MY, Zhao Y, Zhang JH. t(4;11) translocation in hyperdiploid de novo adult acute myeloid leukemia: A case report. World J Clin Cases 2022; 10:11980-11986. [PMID: 36405254 PMCID: PMC9669862 DOI: 10.12998/wjcc.v10.i32.11980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 09/23/2022] [Accepted: 10/20/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND MLL gene rearrangement is a common genetic abnormality of acute myeloid leukemia (AML), which predicts poor prognosis and is important in clinical diagnosis. MLL rearrangement involves many chromosomes, among which, t(4;11) translocation is rare in AML. The present case was t(4;11) AML, accompanied by a hyperdiploid karyotype. Such cases have not been reported previously.
CASE SUMMARY An adult male with self-reported symptoms of fatigue, febrility and hyperleukocytosis was diagnosed with AML by morphology and confirmed by immunophenotype analysis. Uncommonly, chromosomal and fluorescence in situ hybridization (FISH) analysis showed a hyperdiploid karyotype with t(4;11) translocation and MLL rearrangement, and a negative MLL–AF4 fusion gene result. The patient died of respiratory and circulatory failure 5 days after diagnosis.
CONCLUSION t(4;11) AML with hyperdiploid karyotype has not been reported. In this case, t(4;11) was only detected by karyotype analysis and FISH, suggesting their importance in MLL rearrangement detection.
Collapse
Affiliation(s)
- Min-Yu Zhang
- Hematology Laboratory, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
| | - Yue Zhao
- Hematology Laboratory, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
| | - Ji-Hong Zhang
- Hematology Laboratory, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
| |
Collapse
|
2
|
Altahan R, Altahan S, Khalil S. Non-acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17). Clin Case Rep 2019; 7:558-563. [PMID: 30899494 PMCID: PMC6406162 DOI: 10.1002/ccr3.2044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 11/28/2018] [Accepted: 12/15/2018] [Indexed: 12/19/2022] Open
Abstract
t(11;17) is a rare but recognized finding usually found in Acute Promyelocytic Leukemia with variant RARA translocation (APLv). We present a case of Acute Myeloid Leukemia with t(11;17) that has different break points than those occurring in APLv. The diagnosis of acute myeloid leukemia, not otherwise specified, acute monoblastic leukemia was reached after a thorough investigation. Reaching the correct diagnosis and distinguishing these two entities are essential as they have different management, prognosis, and overall survival.
Collapse
Affiliation(s)
- Rahaf Altahan
- Hematology Unit, Department of Pathology and Laboratory MedicineKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| | - Shatha Altahan
- Hematology Unit, Department of Pathology and Laboratory MedicineKing Khalid University HospitalRiyadhSaudi Arabia
| | - Salem Khalil
- Hematology Unit, Department of Pathology and Laboratory MedicineKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| |
Collapse
|
3
|
Yang H, Cao T, Gao L, Wang L, Zhu C, Xu Y, Jing Y, Zhu H, Lv N, Yu L. The incidence and distribution characteristics of MLL rearrangements in Chinese acute myeloid leukemia patients by multiplex nested RT-PCR. Technol Health Care 2018; 25:259. [PMID: 28582914 DOI: 10.3233/thc-171329] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Occurrence of MLL (Mixed Lineage Leukemia) gene rearrangements indicates poor prognosis in acute myeloid leukemia (AML) patients. This is the first study to report the positive rate and distribution characteristics of MLL rearrangements in AML patients in north China. We used multiplex nested real time PCR (RT-PCR) to screen for incidence of 11 MLL rearrangements in 433 AML patients. Eleven MLL rearrangements included (MLL-PTD, MLL-AF9, MLL-ELL, MLL-AF10, MLL-AF17, MLL-AF6, MLL-ENL, MLL-AF1Q, MLL-CBP, MLL-AF1P, MLL-AFX1). There were 68 AML patients with MLL rearrangements, and the positive rate was 15.7%. MLL-PTD (4.84%) was detected in 21 patients, MLL-AF9 in 15, (3.46%), MLL-ELL in 10 (2.31%), MLL-AF10 in 8 (1.85%), MLL-AF1Q in 2 (0.46%), 3 cases each of MLL-AF17, MLL-AF6, MLL-ENL (0.69% each), a and single case each of MLL-CBP, MLL-AF1P, and MLL-AFX1 (0.23% each). The highest rate of MLL rearrangements was found in 24 patients with M5 subtype AML, occurring in 24 cases (35.3%). MLL rearrangements occurred in 21 patients with M2 subtype AML (30.9%), and in 10 patients with M4 subtype AML (14.7%). Screening fusion genes by multiplex nested RT-PCR is a convenient, fast, economical, and accurate method for diagnosis and predicting prognosis of AML.
Collapse
Affiliation(s)
- Hua Yang
- Department of Hematology, The Chinese PLA General Hospital, Beijing 100853, China
| | - Tingting Cao
- Department of Hematology, The Chinese PLA General Hospital, Beijing 100853, China
| | - Li Gao
- Department of Hematology, China-Japan Friendship Hospital, Beijing 100029, China
| | - Lili Wang
- Department of Hematology, The Chinese PLA General Hospital, Beijing 100853, China
| | - Chengying Zhu
- Department of Hematology, The Chinese PLA General Hospital, Beijing 100853, China
| | - Yuanyuan Xu
- Department of Hematology, The Chinese PLA General Hospital, Beijing 100853, China
| | - Yu Jing
- Department of Hematology, The Chinese PLA General Hospital, Beijing 100853, China
| | - Haiyan Zhu
- Department of Hematology, The Chinese PLA General Hospital, Beijing 100853, China
| | - Na Lv
- Department of Hematology, The Chinese PLA General Hospital, Beijing 100853, China
| | - Li Yu
- Department of Hematology, The Chinese PLA General Hospital, Beijing 100853, China
| |
Collapse
|
4
|
Gong XY, Wang Y, Liu BC, Wei H, Li CW, Li QH, Zhao JW, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Li Y, Gu RX, Qiu SW, Mi YC, Wang JX. [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2018; 39:9-14. [PMID: 29551026 PMCID: PMC7343107 DOI: 10.3760/cma.j.issn.0253-2727.2018.01.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Indexed: 01/27/2023]
Abstract
Objective: To analyze the clinical and laboratory characteristics, and prognosis of adult acute myeloid leukemia (AML) patients with MLL gene rearrangements. Methods: The medical records of 92 adult AML patients with MLL gene rearrangements from January 2010 to December 2016 were retrospectively analyzed. Results: 92 cases (6.5%) with MLL gene rearrangements were identified in 1 417 adult AML (Non-M(3)) patients, the median age of the patients was 35.5 years (15 to 64 years old) with an equal sex ratio, the median WBC were 21.00(0.42-404.76)×10(9)/L, and 78 patients (84.8%) were acute monoblastic leukemia according to FAB classification. Eleven common partner genes were detected in 32 patients, 9 cases (28.1%) were MLL/AF9(+), 5 cases (15.6%) were MLL/AF6(+), 5 cases (15.6%) were MLL/ELL(+), 2 cases (6.3%) were MLL/AF10(+), 1 case (3.1%) was MLL/SETP6(+), and the remaining 10 patients' partner genes weren't identified. Of 92 patients, 83 cases with a median follow-up of 10.3 (0.3-74.0) months were included for the prognosis analysis, the complete remission (CR) rate was 85.5% (71/83), the median overall survival (OS) and relapse free survival (RFS) were 15.4 and 13.1 months, respectively. Two-year OS and RFS were 36.6% and 29.5%, respectively. Of 31 patients underwent allogeneic hematopoietic stem-cell transplantation (allo-HSCT), two-year OS and RFS for patients received and non-received allo-HSCT were 57.9% and 21.4%, 52.7% and 14.9%, respectively (P<0.001). Among patients with partner genes tested, 9 of 32 cases (28.1%) were MLL/AF9(+), the median follow-up was 6.0(4.1-20.7) months. 3 patients with MLL/AF9 underwent allo-HSCT. 23 cases (71.9%) were non- MLL/AF9(+), the median follow-up was 7.8 (0.3-26.6) months. 14 patients (60.1%) with non-MLL/AF9 underwent allo-HSCT. One-year OS for patients with MLL/AF9 and non-MLL/AF9 were 38.1% and 55.5%, respectively (P=0.688). Multivariate analysis revealed that high WBC (RR=1.825, 95% CI 1.022-3.259, P=0.042), one cycle to achieve CR (RR=0.130, 95% CI 0.063-0.267, P<0.001), post-remission treatment with allo-HSCT (RR=0.169, 95% CI 0.079-0.362, P<0.001) were independent prognostic factors affecting OS. Conclusions: AML with MLL gene rearrangements was closely associated with monocytic differentiation, and MLL/AF9 was the most frequent partner gene. Conventional chemotherapy produced a high response rate, but likely to relapse, allo-HSCT may have the potential to further improve the prognosis of this group of patients.
Collapse
Affiliation(s)
- X Y Gong
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Wang Q, Zhuang L, Li P, Niu Q, Zhu P, He MX, Jiang H, Liu CC, Wang MJ, Chen L, Cheng H, Ma Y, Hu XX, Hu YP, Xu XP. Establishment of a novel human lymphoblastic cell strain with the long arm of chromosome 11 aberration without MLL rearrangement. Sci Rep 2017; 7:867. [PMID: 28408741 PMCID: PMC5429836 DOI: 10.1038/s41598-017-00874-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 03/20/2017] [Indexed: 11/10/2022] Open
Abstract
At present, all cell strains derived from acute lymphoblastic leukemia (ALL) patients with the long arm of chromosome 11 aberration are accompanied with mixed lineage leukemia (MLL) gene rearrangement. In this study, we established a permanent ALL cell strain CHH-1 with the long arm of chromosome 11 aberration and without MLL rearrangement, hoping that it could be used for the research of ALL with such genetic abnormality. CHH-1 cell strain was certified through morphology, immunophenotype, genetics and immunoglobulin (Ig) gene rearrangement analysis. Cell characteristics including tumorigenic ability, semisolid colony forming ability, telomerase activity, autocrine and invasion were further detected. Cells were with an add(11)(q23) structural abnormality without MLL rearrangement, and were consistent with the genetic abnormality of the patient. In addition, these cells had features of tumor-forming ability, high colony forming capacity, unique cytokine autocrine mode, high telomerase activity, and high invasion ability. CHH-1 may prove to be a useful cell model for the research of human leukemia with genetic aberration in chromosome 11, and help explore the role of such genetic abnormality in the pathogenesis, progression and prognosis of ALL, and in developing new target drugs.
Collapse
Affiliation(s)
- Qian Wang
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Lin Zhuang
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Pei Li
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Qiang Niu
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Ping Zhu
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Miao-Xia He
- Department of Pathology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Hui Jiang
- Department of Pathology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Chang-Cheng Liu
- Department of Cell Biology, Second Military Medical University, No. 800 Xiangyin Road, Shanghai, 200433, P.R. China
| | - Min-Jun Wang
- Department of Cell Biology, Second Military Medical University, No. 800 Xiangyin Road, Shanghai, 200433, P.R. China
| | - Li Chen
- Department of Hematology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Hui Cheng
- Department of Hematology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Yan Ma
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China
| | - Xiao-Xia Hu
- Department of Hematology, ChangHai Hospital Affiliated of Second Military Medical University, No. 168 Changhai Road, Shanghai, 200433, P.R. China
| | - Yi-Ping Hu
- Department of Cell Biology, Second Military Medical University, No. 800 Xiangyin Road, Shanghai, 200433, P.R. China.
| | - Xiao-Ping Xu
- Department of Hematology, HuaShan Hospital Affiliated of FuDan University, No. 12 Middle WuLumuqi Road, Shanghai, 200040, P.R. China.
| |
Collapse
|
6
|
Yang H, Huang S, Zhu CY, Gao L, Zhu HY, Lv N, Jing Y, Yu L. The Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements. Med Sci Monit 2016; 22:2315-23. [PMID: 27373985 PMCID: PMC4941891 DOI: 10.12659/msm.899186] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Acute myeloid leukemia (AML) patients with mixed lineage leukemia (MLL) gene rearrangements always had a very poor prognosis. In this study, we report the incidence of MLL rearrangements in AML patients using gene analysis, as well as the clinical significance and prognostic features of these rearrangements. MATERIAL AND METHODS This retrospective study took place from April 2008 to November 2011 in the People's Liberation Army General Hospital. A total 433 AML patients were screened by multiple nested reverse transcription polymerase chain reaction (RT-PCR) to determine the incidence of the 11 MLL gene rearrangements. There were 68 cases of MLL gene rearrangements, for a positive rate of 15.7%. A total of 24 patients underwent allogeneic hematopoietic stem cell transplantation (Allo-HSCT), and 34 patients received at least 4 cycles of chemotherapy. Ten patients were lost to follow-up. RESULTS The median follow-up was 29 months. The complete remission (CR) rate was 85.4%. The overall survival (OS) was 57.4±5.9 months for the Allo-HSCT group and 21.0±2.1 months for the chemotherapy group. The Allo-HSCT group had superior survival compared with the chemotherapy group (5-year OS: 59±17% vs. 13±8%, P<0.01; 5-year disease-free survival [DFS]: 65±10% vs. 40±16%, P>0.05). Multivariate analysis showed that transplantation, platelets >50×10^9/L at onset, and CR are associated with a better OS in MLL rearranged AML patients. Patients with thrombocytopenia and extramedullary involvement were prone to relapse. CONCLUSIONS Our results suggest that Allo-HSCT is superior to chemotherapy alone for treating MLL rearranged AML patients. Patients treated with Allo-HSCT have a better prognosis and a longer survival. CR is an independent prognostic factor for OS, and extramedullary involvement is an independent prognostic factor for DFS. MLL rearranged AML patients with thrombocytopenia at onset <50×10^9 had very bad OS and DFS.
Collapse
Affiliation(s)
- Hua Yang
- Department of Hematology and BMT, Chinese PLA General Hospital, Beijing, China (mainland)
| | - Sai Huang
- Department of Hematology and BMT, Chinese PLA General Hospital, Beijing, China (mainland)
| | - Cheng-Ying Zhu
- Department of Hematology and BMT, Chinese PLA General Hospital, Beijing, China (mainland)
| | - Li Gao
- Department of Hematology and BMT, Chinese PLA General Hospital, Beijing, China (mainland)
| | - Hai-Yan Zhu
- Department of Hematology and BMT, Chinese PLA General Hospital, Beijing, China (mainland)
| | - Na Lv
- Department of Hematology and BMT, Chinese PLA General Hospital, Beijing, China (mainland)
| | - Yu Jing
- Department of Hematology and BMT, Chinese PLA General Hospital, Beijing, China (mainland)
| | - Li Yu
- Department of Hematology and BMT, Chinese PLA General Hospital, Beijing, China (mainland)
| |
Collapse
|
7
|
Hagag AA, Shebl SS, El-Fadaly NH. Frequency of 11q23/MLL gene rearrangement in Egyptian childhood acute myeloblastic leukemia: Biologic and clinical significance. South Asian J Cancer 2014; 3:206-8. [PMID: 25422805 PMCID: PMC4236697 DOI: 10.4103/2278-330x.142964] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
BACKGROUND Molecular cytogenetic abnormalities involving 11q23 are among the most common cytogenetic abnormalities in acute myeloid leukemia (AML) patients. AIM OF THE WORK we aimed to evaluate the frequency of MLL/AF9 fusion gene in de novo AML patients, its impact on clinical features, and its prognostic significance. PATIENTS AND METHODS Twenty-eight children patients with AML and 20 healthy controls were subjected to complete clinical examination and laboratory investigations including, complete hemogram and bone marrow (BM) examination. Diagnosis was based on FAB morphologic and immunophenotypic criteria. Detection of (MLL/AF9) fusion gene was assessed by dual color fluorescent in situ hybridization (FISH). Follow-up were carried out clinically and by blast count in BM, and response to therapy to detect the outcome of the disease. RESULTS The incidence of MLL-fusion gene MLL/AF9 in AML cases was about (6/28) (21%). Four patients with MLL/AF9 fusion gene were newly diagnosed, two cases were at relapse and no patient at remission showed positivity. As regard the clinical outcome, five out of six MLL positive cases died, three of them during induction and two during relapse. The FAB AML subtypes with MLL/AF9 fusion were one M2, three M4, and two M5. CONCLUSION MLL-fusion gene MLL/AF9 was found in about 21% of studied AML patients when assessed by FISH technique and this is of high clinical relevance as most of these abnormalities have been associated with poor prognosis.
Collapse
Affiliation(s)
| | - Shebl S Shebl
- Department of Pediatrics, Pediatric Hematology-Oncology Unit, Egypt
| | | |
Collapse
|
8
|
11q23 abnormalities in adult Chinese patients with hematological malignancies. Med Oncol 2014; 31:115. [PMID: 25008067 DOI: 10.1007/s12032-014-0115-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Accepted: 07/01/2014] [Indexed: 10/25/2022]
Abstract
The mixed lineage leukemia (MLL) gene on chromosome region 11q23 is frequently involved in chromosomal translocations associated with various human hematologic malignant neoplasms. The aim of this study was to investigate the profile of 11q23 abnormalities in adult Chinese patients with hematological malignancies. In this study, 11q23 abnormalities were detected by cytogenetic and fluorescence in situ hybridization (FISH) approaches in 77 out of a total of 2,404 adult Chinese patients with leukemia, lymphoma, and myelodysplastic syndrome (MDS). 11q23 abnormalities were found in 5.31 % of the acute myeloid leukemia (AML) cases, 5.71 % of the acute lymphoid leukemia (ALL) cases, 2.94 % of lymphoma cases, and 1.24 % of MDS cases. Of the patients with 11q23 abnormalities, 59.74 % showed rearrangement or deletion of the MLL gene by FISH; a novel 11q23 rearrangement, der(6)t(6;11)(q23;q23), was discovered in one case. Our data showed that t(11;19)(q23;p13.1) was the most frequent translocation in AML patients and t(4;11)(q21;q23) was the most frequent translocation in ALL patients. FLT-ITD mutations were detected in three out of 33 AML patients with 11q23 abnormalities (9.09 %). The Kaplan-Meier survival analysis further showed that the 11q23 aberration was a poor prognostic factor for AML. The median survival times in the 11q23 aberration subgroup, the normal karyotype subgroup, and the subgroup with other abnormalities were 7.4, 11.3, and 16.8 months, respectively (P = 0.0464). Our study found one novel 11q23 rearrangement, der(6)t(6;11)(q23;q23), and demonstrated the profile of 11q23 abnormalities in adult Chinese patients with hematological malignancies.
Collapse
|
9
|
Bäumer N, Krause A, Köhler G, Lettermann S, Evers G, Hascher A, Bäumer S, Berdel WE, Müller-Tidow C, Tickenbrock L. Proteinase-Activated Receptor 1 (PAR1) regulates leukemic stem cell functions. PLoS One 2014; 9:e94993. [PMID: 24740120 PMCID: PMC3989293 DOI: 10.1371/journal.pone.0094993] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2014] [Accepted: 03/21/2014] [Indexed: 12/30/2022] Open
Abstract
External signals that are mediated by specific receptors determine stem cell fate. The thrombin receptor PAR1 plays an important role in haemostasis, thrombosis and vascular biology, but also in tumor biology and angiogenesis. Its expression and function in hematopoietic stem cells is largely unknown. Here, we analyzed expression and function of PAR1 in primary hematopoietic cells and their leukemic counterparts. AML patients' blast cells expressed much lower levels of PAR1 mRNA and protein than CD34+ progenitor cells. Constitutive Par1-deficiency in adult mice did not affect engraftment or stem cell potential of hematopoietic cells. To model an AML with Par1-deficiency, we retrovirally introduced the oncogene MLL-AF9 in wild type and Par1−/− hematopoietic progenitor cells. Par1-deficiency did not alter initial leukemia development. However, the loss of Par1 enhanced leukemic stem cell function in vitro and in vivo. Re-expression of PAR1 in Par1−/− leukemic stem cells delayed leukemogenesis in vivo. These data indicate that Par1 contributes to leukemic stem cell maintenance.
Collapse
Affiliation(s)
- Nicole Bäumer
- Department of Medicine, Hematology/Oncology, University of Muenster, Muenster, Germany
| | - Annika Krause
- Department of Medicine, Hematology/Oncology, University of Muenster, Muenster, Germany
| | - Gabriele Köhler
- Gerhard Domagk Institute for Pathology, University of Muenster, Muenster, Germany
| | - Stephanie Lettermann
- Department of Medicine, Hematology/Oncology, University of Muenster, Muenster, Germany
| | - Georg Evers
- Department of Medicine, Hematology/Oncology, University of Muenster, Muenster, Germany
| | - Antje Hascher
- Hochschule Hamm-Lippstadt, University of Applied Science, Hamm, Germany
| | - Sebastian Bäumer
- Department of Medicine, Hematology/Oncology, University of Muenster, Muenster, Germany
| | - Wolfgang E. Berdel
- Department of Medicine, Hematology/Oncology, University of Muenster, Muenster, Germany
| | - Carsten Müller-Tidow
- Department of Medicine, Hematology/Oncology, University of Muenster, Muenster, Germany
- Interdisciplinary Center for Clinical Research IZKF, University of Muenster, Muenster, Germany
- Dept. of Medicine IV, Hematology and Oncology, University of Halle, Halle, Germany
- * E-mail: (CMT); (LT)
| | - Lara Tickenbrock
- Department of Medicine, Hematology/Oncology, University of Muenster, Muenster, Germany
- Hochschule Hamm-Lippstadt, University of Applied Science, Hamm, Germany
- * E-mail: (CMT); (LT)
| |
Collapse
|
10
|
Acute myeloid leukemia with minimal differentiation: Unusual cytogenetics, morphology, phenotype and clinical course. Leuk Res 2012; 36:e133-6. [DOI: 10.1016/j.leukres.2012.03.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2011] [Revised: 02/28/2012] [Accepted: 03/12/2012] [Indexed: 01/20/2023]
|
11
|
Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leuk Res 2011; 35:351-7. [PMID: 20691474 DOI: 10.1016/j.leukres.2010.07.018] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2010] [Revised: 06/24/2010] [Accepted: 07/12/2010] [Indexed: 02/03/2023]
Abstract
Deletions of chromosome 11q[del(11q)] as part of a non-complex karyotype are infrequent in myelodysplastic syndromes (MDS), leaving the clinicopathologic and genetic features largely undefined. From three large medical centers over a 10-year period, we identified 32 MDS cases where del(11q) was present either as a sole (n=23) or associated with another abnormality (n=9), showing an overall 0.6% frequency in MDS. These patients included 15 men and 17 women, with a median age of 68 years. Three were therapy-related, and 29 were primary MDS. These cases were characterized by transfusion-dependent anemia (65%); frequent ring sideroblasts (RS) (59%); bone marrow hypocellularity (22%), and less severe thrombocytopenia. With a median follow-up of 32 months, 9/24 (38%) cases progressed to acute myeloid leukemia (AML), and the overall survival (OS) was 35 months (3-105). Fluorescence in situ hybridization (FISH) showed MLL deletion in 6/10 cases, but no cryptic MLL translocations in all 15 MDS cases tested. In contrast, FISH performed in AML with del(11q) showed MLL rearrangement in 3/17 (18%) cases. In summary, del(11)q occurring in a non-complex karyotype is predominantly associated with primary MDS, lack of cryptic MLL rearrangements, and shows characteristic clinicopathological features. These clinicopathological features are likely attributed to commonly deleted regions of 11q and their involved genes.
Collapse
|
12
|
Kakihana K, Kubo F, Wakabayashi S, Kurosu T, Miki T, Murakami N, Miura O. A novel variant form of MLL-ELL fusion transcript with t(11;19)(q23;p13.1) in chronic myelomonocytic leukemia transforming to acute myeloid leukemia. ACTA ACUST UNITED AC 2008; 184:109-12. [PMID: 18617060 DOI: 10.1016/j.cancergencyto.2008.04.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2008] [Revised: 03/21/2008] [Accepted: 03/28/2008] [Indexed: 10/21/2022]
Abstract
MLL located at 11q23 is fused with a variety of partner genes by recurrent chromosomal translocations in acute leukemias. ELL, the MLL partner gene located on chromosome 19p13.1, encodes an RNA polymerase II transcriptional elongation factor, which also possesses the N-terminal region involved in the inhibition of transcription initiation. Here we report a case of chronic myelomonocytic leukemia (CMML) with a 46,XY,t(11;19)(q23;p13.1) karyotype that transformed to acute myeloid leukemia (AML) without showing any karyotypic evolution. Interphase fluorescent in situ hybridization analysis showed the split MLL signals in 95% of bone marrow cells when the diagnosis of CMML was made and the percentage of blasts was 1.2%. Sequence analysis of reverse-transcriptional polymerase chain reaction product revealed a novel variant form of MLL-ELL transcript in which MLL exon 10 was fused to ELL exon 3. MLL has been fused to ELL exon 2 in all the previously reported MLL-ELL transcripts, which have always been associated with AML. It is deduced that the variant form of MLL-ELL may be defective not only in inhibition of transcription initiation, but also in transcriptional elongation. Thus, a possibility is raised that the unique clinical presentation of the present case with t(11;19)(q23;p13.1) might be related to the variant form of MLL-ELL.
Collapse
Affiliation(s)
- Kazuhiko Kakihana
- Department of Hematology, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyoku, Tokyo 113-8519, Japan
| | | | | | | | | | | | | |
Collapse
|
13
|
Chatterjee T, Chowdhary GS, Singh R, Srinivas V, Bandyopadhyay S, Kataria VK, Anand KP. Acute Myeloid Leukaemia : AML M0 with 11q deletion. Med J Armed Forces India 2008; 64:179-80. [PMID: 27408130 DOI: 10.1016/s0377-1237(08)80075-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2006] [Accepted: 11/17/2007] [Indexed: 10/18/2022] Open
Affiliation(s)
- T Chatterjee
- Classified Specialist (Path) and Haematopathologist, Command Hospital (Eastern Command)
| | - G S Chowdhary
- Classified Specialist (Med) and Medical Oncologist, Command Hospital (Eastern Command)
| | - R Singh
- Classified Specialist (Med) and Medical Oncologist, Command Hospital (Eastern Command)
| | - V Srinivas
- Reader (Department of Pathology), AFMC, Pune
| | - S Bandyopadhyay
- Senior Advisor (Path & Biochem), Command Hospital (Eastern Command)
| | - V K Kataria
- DDG (Pensions), Office of DGAFMS, L Block, AHQ, New Delhi
| | | |
Collapse
|
14
|
Vega-Ruiz A, O'Brien S, Cortes J, Kebriaei P, Thomas D, Kantarjian H, Ravandi F. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leuk Res 2008; 32:1468-71. [PMID: 18355919 DOI: 10.1016/j.leukres.2008.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2007] [Revised: 02/05/2008] [Accepted: 02/06/2008] [Indexed: 10/22/2022]
Abstract
The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid leukemia but not in patients with Ph-positive ALL. Here, we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic, cytogenetic, and major molecular responses. The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL.
Collapse
Affiliation(s)
- Arturo Vega-Ruiz
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | |
Collapse
|
15
|
Siew-Gek Lee A, Rudduck-Sivaswaren C, Khun-Hong Lie D, Li-Ming Chua C, Tien SL, Morsberger L, Griffin CA. Overlapping deletion regions at 11q23 in myelodysplastic syndrome and chronic lymphocytic leukemia, characterized by a novel BAC probe set. ACTA ACUST UNITED AC 2004; 153:151-7. [PMID: 15350305 DOI: 10.1016/j.cancergencyto.2004.01.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2003] [Revised: 01/05/2004] [Accepted: 01/07/2004] [Indexed: 10/26/2022]
Abstract
Translocations or deletions involving the 11q23 region have been observed in acute lymphoblastic leukemia (ALL), acute myelocytic leukemia (AML), myelodysplastic syndrome (MDS), and chronic lymphocytic leukemia (CLL). BAC probes encompassing the D11S29 and D11S924 markers and flanking the MLL gene were used in dual color fluorescence in situ hybridization. Fifteen patients with hematologic malignancies and cytogenetic abnormalities of 11q23 were analyzed. The BAC and MLL probes demonstrated split signals in five of 7 ALL or AML cases with translocations of 11q23. Of the remaining 2 cases, one had normal signals for both probe sets and the other had a submicroscopic deletion of the MLL 3' region. In one case of AML with del(11)(q23), deletion of the MLL 3' region and the region telomeric to the MLL gene was seen. Three CLL cases with deletion of part or the entire 11q23 region showed deletion of one copy of MLL, but retention of the region telomeric to MLL. However, in four MDS cases with deletions involving the 11q23 region, deletions of both the MLL gene and the flanking regions of the MLL gene were observed. Hence, the deletions on 11q23 are different but overlapping for CLL and MDS, implicating different genes involved for these diseases.
Collapse
Affiliation(s)
- Ann Siew-Gek Lee
- Division of Medical Sciences, National Cancer Centre, Division of Medical Sciences, 11 Hospital Drive, 169610 Singapore.
| | | | | | | | | | | | | |
Collapse
|
16
|
Cox MC, Panetta P, Venditti A, Del Poeta G, Maurillo L, Tamburini A, Del Principe MI, Amadori S. Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+/MLL+ translocation in leukaemia. Br J Haematol 2003; 121:953-5. [PMID: 12786810 DOI: 10.1046/j.1365-2141.2003.04382.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
17
|
Kim HJ, Cho HI, Kim EC, Ko EK, See CJ, Park SY, Lee DS. A study on 289 consecutive Korean patients with acute leukaemias revealed fluorescence in situ hybridization detects the MLL translocation without cytogenetic evidence both initially and during follow-up. Br J Haematol 2002; 119:930-9. [PMID: 12472570 DOI: 10.1046/j.1365-2141.2002.03937.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Translocations involving the MLL gene on the chromosome 11 (11q23) are frequently observed in acute leukaemia. The detection of this genetic change has a unique significance as a result of its implication of poor prognosis. To reveal the utility of fluorescence in situ hybridization (FISH) in detecting the MLL translocation, we analysed 289 consecutive Korean patients (children and adults) with acute leukaemias using both conventional cytogenetic analysis (CC) and FISH, placing an emphasis on the result discrepancies. Twenty-two of 289 patients (7.6%) had the 11q23/MLL translocation. In nine of 22 patients (41%), only FISH detected the translocation. In eight of these 22 patients, a total of 19 follow-up examinations were performed, of which FISH detected a significant level of leukaemic cells harbouring the MLL translocation in five patients (26%) without cytogenetic evidence. In addition to the MLL translocation, FISH detected submicroscopic amplification, partial deletion of the MLL gene and trisomy 11 in 12 patients without cytogenetic evidence. In summary, up to 41% of the MLL translocations at initial work-up and 26% during follow-up were detected by FISH without cytogenetic evidence. Thus, we recommend that MLL FISH should be performed in the diagnosis and monitoring of acute leukaemias in combination with CC.
Collapse
Affiliation(s)
- Hee Jin Kim
- Department of Clinical Pathology, Department of Internal Medicine, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | | | | | | | | | | | | |
Collapse
|
18
|
Shevde LA, Samant RS, Goldberg SF, Sikaneta T, Alessandrini A, Donahue HJ, Mauger DT, Welch DR. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002; 273:229-39. [PMID: 11822878 DOI: 10.1006/excr.2001.5452] [Citation(s) in RCA: 115] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
We recently identified a novel metastasis suppressor gene, BRMS1, in breast cancer. Since the BRMS1 gene maps to chromosome 11q13.1-q13.2 and since chromosome 11q defects have been described in various stages of human melanoma progression, we hypothesized that BRMS1 may function as a tumor or metastasis suppressor in melanomas as well. Quantitative real-time RT-PCR revealed that BRMS1 mRNA expression was high in melanocytes, considerably reduced in early melanoma-derived cell lines, and barely detectable in advanced/metastatic cell lines. Stable transfectants of BRMS1 in the human melanoma cell lines MelJuSo and C8161.9 did not alter the tumorigenicity of either cell line, but significantly suppressed metastasis compared to vector-only transfectants. Orthotopic tumors continued to express BRMS1, but expression was lost in lung metastases. In vitro morphology, growth rate, and histology of BRMS1 transfectants were similar to controls. BRMS1 transfectants were less invasive in a collagen sandwich assay and had restored homotypic gap junctional intercellular communication (GJIC). Thus, BRMS1 functions as a metastasis suppressor in more than one tumor type (i.e., breast carcinoma and cutaneous melanoma) by modifying several metastasis-associated phenotypes.
Collapse
Affiliation(s)
- Lalita A Shevde
- Jake Gittlen Cancer Research Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033-2390, USA
| | | | | | | | | | | | | | | |
Collapse
|